Good morning, ladies and gentlemen, and thank you for standing by. My name is Kelvin, and I will be your conference operator today. At this time, I would like to welcome everyone to the Mettler-Toledo International Inc. First Quarter 2025 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, please press star 1 again. Thank you. I would now like to turn the call over to Adam Uhlman, head of investor relations. Please go ahead.

Hey. Thanks, Kelvin, and good morning, everyone. I appreciate you joining us. On the call with me today is Patrick Kaltenbach, our Chief Executive Officer, and Shawn Vadala, our Chief Financial Officer. Let me cover some administrative matters. This call will be webcast and available for replay on our website at mt.com. A copy of the press release and presentation that we'll refer to on today's call is also available on our website. This call will include forward-looking statements within the meaning of the U.S. Securities Act of 1933 and the U.S. Securities Exchange Act of 1934. These statements involve risks, uncertainties, and other factors that may cause our actual results, financial condition, performance, and achievements to be materially different from those expressed or implied by any forward-looking statements. For a discussion of these risks and uncertainties, please see our recent annual report on Form 10-K and quarterly and current reports filed with the SEC. The company disclaims any obligation or undertaking to provide any updates or revisions to any forward-looking statement except as required by law. On today's call, we may use non-GAAP financial measures, and reconciliation of these non-GAAP measures to the most directly comparable GAAP measure is provided in the 8-K and is available on our website. Let me now turn the call over to Patrick.

Evan, and good morning, everyone. We appreciate you joining our call today. Last night, we reported our first quarter financial results, the details of which are outlined for you on page three of our presentation. We had a good start to the year with solid growth in our laboratory business, excluding the recovery of delayed shipments in the first quarter of 2024. Additionally, strong execution of our margin expansion strategies led to better-than-expected earnings for the quarter. However, the ongoing global trade disputes and tariffs have significantly increased uncertainty in global customer demand. We also estimate cross-incremental global tariff costs of $115 million on an annual basis and are implementing mitigation actions this year that will fully offset these costs next year. We are confident in our strong culture of operational excellence, and our highly agile team will continue to perform well in this dynamic environment, and we will benefit from the breadth of our innovative product portfolio and strategic programs. Let me now turn the call over to Shawn to cover the financial results and our guidance, and then I will come back with some additional commentary on the business and our outlook.

Hey, thanks, Patrick, and good morning, everyone. Sales in the quarter were $884 million, which represented a decrease in local currency of 3%. Excluding the impact of shipping delays from February that were recovered in February, local currency sales grew 3%. On a U.S. dollar reported basis, sales declined 5%. On slide number four, we show sales growth by region. Local currency sales declined 1% in The Americas, 7% in Europe, and 2% in Asia rest of the world. Local currency sales were flat in China during the quarter. Excluding the impact of shipping delay recoveries in the prior year, local currency sales grew 3% in The Americas, 4% in Europe, and 3% in Asia rest of the world, including 3% growth in China. On slide number five, we summarize local currency sales growth by product area. For the quarter, laboratory sales decreased 3% and industrial declined 1%, with core industrial down 6% and product inspection up 8%. Food retail declined 12% in the quarter. Excluding the impact of shipping recoveries last year, we estimate our laboratory sales grew 5%, industrial grew 2%, with core industrial down 2%, and product inspection up 8%. And food retail declined 5%. Service sales increased 6% in local currency in the first quarter. Let me now move to the rest of the P&L, which is summarized on Slide number six. Gross margin was 59.5% in the quarter, an increase of 30 basis points as positive price realization and benefits from our sterndrive program were offset in part by lower volume. We estimate gross margin expanded 90 basis points excluding shipping delays. R&D amounted to $46 million in the quarter, which is a 2% increase in local currency over the prior year. SG&A amounted to $243 million, a 5% increase in local currency over the prior year and includes sales and marketing investments and timing of expenses. Adjusted operating profit amounted to $237 million in the quarter, down 11% from the prior year. Adjusted operating margin was 26.8%, which represents a decrease of two ten basis points over the prior year. Excluding the impact of shipping delay recoveries in the prior year, our operating margin expanded 50 basis points on 3% sales growth in the quarter. A couple of final comments on the P&L. Amortization amounted to $17 million in the quarter, interest expense was $17 million, and adjusted other income amounted to $3 million. Our effective tax rate was 19% in the quarter. This rate is before discrete items and is adjusted for the timing of stock option exercises. Fully diluted shares amounted to 20,900,000, which is approximately a 3% decline from the prior year. Adjusted EPS for the quarter was $8.19, an 8% decrease over the prior year. Adjusted EPS growth was 11%, excluding a headwind to EPS growth of approximately 18% from the recovery of delayed shipments and a 1% headwind from foreign exchange. On a reported basis in the quarter, EPS was $7.81 compared to $8.24 in the prior year. Reported EPS in the quarter included $0.23 of purchase intangible amortization and $0.15 of restructuring costs. That covers the P&L, and let me now comment on adjusted free cash flow, which amounted to $180 million in the quarter, a 1% increase on a per-share basis and was impacted by higher bonus payments of $36 million related to prior year performance. DSO was thirty-five days, while ITO was 4.2 times. Let me now turn to our guidance for the second quarter and for the full year 2025. As you review our guidance, please keep in mind the following factors. First, our guidance assumes U.S. import tariffs as well as the impact of Rutella tariffs from other countries will remain in effect at current levels. Geopolitical tensions are elevated and include the potential for new tariffs or retaliatory tariffs that we have not factored into our guidance. As of today, we estimate our incremental global tariff costs at approximately $115 million on an annualized basis, which already includes initial actions we have taken to lower our gross exposure. Secondly, we are taking various actions to offset the impact of higher tariffs, including supply chain optimization, cost savings, price increases, and surcharges. Our actions are expected to fully offset tariff costs on an annualized basis, but we will have a headwind in our gross margin in 2025, especially Q2, until the full benefit is realized.

Thanks, Shawn. Let me start with some comments on our operating businesses, which will exclude the impact of the recovery of delayed shipments in the first quarter of last year. I will start with lab, which had solid growth in the quarter. We continue to benefit from recent innovations like our new line of laboratory titrators and thermal analysis instruments, and our sophisticated go-to-market approaches have helped us penetrate underserved market segments. We had strong growth in our process analytics business in this quarter, which continues to benefit from favorable biopharma market trends, especially in single-use technologies and recent innovations like our digital sensors with intelligent sensor management, that provide reliable in-line measurement of critical analytical parameters. Precise analytics, monitoring, and control systems are crucial for optimizing bioprocess operations. By providing real-time data and feedback, our systems can help ensure ideal cell viability, nutrition feeding, and consistent productivity throughout the bioprocess life cycle, from R&D to manufacturing in both reusable and single-use formats. Turning to our industrial business, our underlying sales growth was led by our product inspection business, where our growth initiatives and new portfolio have offset challenging market conditions in the food manufacturing industry. Our innovation investments are well received in the market. Our new innovations have low total cost of ownership and can significantly improve productivity, for example, by enabling much higher line speeds in production and reducing waste, which is more important than ever to protect margins in food manufacturing. Switching to Core Industrial, sales were down slightly excluding the impact of prior year shipment delay recoveries, as industry conditions remain mixed across most end markets. Our team remains active in engaging with customers with cost-saving solutions like our quality control software that improves process control and reduces waste in their manufacturing operations. Our suite of smart terminals helps customers transition manual processes to semi or fully automated process control that includes full traceability for reliable reporting. These solutions are increasingly important for customers looking to expand manufacturing in higher-cost geographies and automate more of their production processes. And lastly, food retail declined as we had expected. Now let me make some additional comments by geography, which will also exclude the impact of last year's shipping recovery. Starting in The Americas, our underlying sales growth was led by strong growth in process analytics and product inspection. This growth was partially offset by lower core industrial sales, against strong growth in the prior year. Turning to Europe, we had underlying sales growth across our businesses with the exception of retail. Our team continues to execute very well, and we have benefited from our innovative portfolio and Spinnaker programs. And finally, Asia rest of the world results were about as expected and grew modestly against easy comparisons. Market conditions in China remain soft, and economic uncertainty is increasing. We continue to leverage our Spinnaker program to identify growth opportunities, and our team remains highly agile to take advantage of opportunities. In summary, we are pleased with the good start to 2025, although we recognize there is increased uncertainty due to tariffs and the potential impact on our end markets and global economic growth. During uncertain times, our strong culture of teamwork, collaboration, and focused execution has been a critical asset that has helped our company successfully navigate uncertainty very well in the past. We also benefit from our business diversity and help customers across their entire value chain, from research and development, scale-up, quality control, and production. We also serve a wide range of diverse end markets, and over 70% of our sales are in core end markets of pharma, biopharma, food manufacturing, and chemicals. No end customer is more than 1% of sales, and we also benefit from our geographic diversity as we sell in over 140 countries around the world. We also have a broad and diverse product offering and have introduced new innovations across a wide range of our portfolio in recent years that provide tangible benefits to customers, significantly enhancing our value proposition. Our automation and digitalization solutions help customers improve their productivity and reduce costs while enhancing compliance with relevant regulations. Additionally, our average price points are low and typically below $10,000, and our large installed base and replacement demand help reduce cyclicality. Approximately 35% of our sales last year were service and consumables, and we are confident our dedicated growth initiatives in this area will remain accretive to our growth and profitability. Our go-to-market approach is also a competitive advantage during periods of increased uncertainty. Our sales and marketing excellence programs, Spinnaker, ensure we are identifying and guiding our sales teams to the most attractive opportunities in the market. For example, we expect to see increased U.S. onshoring investment over the coming years, and we will benefit from these investments. Our strong direct sales force helps us communicate our value proposition directly to end users. Our global supply chain is another important asset. We serve customers around the world with 21 manufacturing locations in seven countries. We also continue to increase the resilience of our manufacturing footprint, which allows us to produce products in multiple regions. U.S. import tariffs represent additional costs we plan to offset with supply chain optimization actions, cost savings, price increases, and surcharges. Our global pricing program is deeply ingrained throughout our organization and is based on a sophisticated set of data analytics and tools that help support our end-to-end pricing process. Our Blue Ocean program has also allowed us to have centralized price administration with robust processes so we can react quickly to changing conditions. Overall, we recognize there's increased uncertainty in the economy, and we remain agile to respond to the changes in the market conditions as necessary. At the same time, we remain convinced of the long-term growth opportunity in our end markets and our ability to gain market share and grow faster than the market, especially in very dynamic market conditions. We remain focused on the things we can control and continue to implement strategies with a good balance of initiatives focused on growth, innovation, and operational excellence. This concludes our prepared remarks. Operator, I'd like now to open the line to questions.

Thank you. Ladies and gentlemen, we will now begin the question and answer session. At this time, I would like to remind everyone to ask a question. If you would like to withdraw your question, please press 1 again. One moment, please, for your first question. Your first question comes from the line of Dan Leonard of UBS. Please go ahead.

Thank you very much. My first question is one on China. Can you update us with your new forecast for revenue growth in China in 2025 and maybe parse that between industrial and lab?

Yeah. Hey, Dan. This is Shawn. I'll take that one. So for China for 2025, for the full year on a reported basis, we expect China to be down slightly. Maybe I'll comment on Q2. We expect Q2 to be down, like, low to mid-single digit. On the full-year basis, you know, we expect that to be kind of, like, up low single digit in terms of the lab business and down low single digit in terms of the industrial business. And for Q2, we expect lab to be down low single digit and industrial to be down mid-single digit. And, hey, this probably is a good parlay into, like, a little bit of our thoughts on guidance. You know, when Patrick talks about uncertainty, clearly, it's probably higher on the list in terms of areas where there's uncertainty. You know, in terms of, like, where we're seeing maybe some caution in the market in terms of customers maybe holding off in terms of investment a little bit here in the second quarter, so we're just a little bit more cautious here in Q2 and how we're thinking about kind of China developing for the rest of the year. You know? But I think going Appreciate that.

Yeah. Okay. And maybe as a follow-up. You mentioned onshoring, and there have been a lot of announcements lately. I don't know, Patrick, if there's any way you could help us better quantify the potential opportunity for Mettler-Toledo International Inc. from various manufacturing onshoring initiatives?

Sure, Dan. I'm happy to take the questions. Look. I mean, the whole reshoring, homeshoring, onshoring, whatever you would call it, is definitely something that will be important for us moving forward. That said, as these companies are starting to restore reshoring programs and, you know, factories are raised, etcetera, we are a bit later in the process. We are not in the initial construction phase, etcetera, involved in with these companies. But we are, of course, talking to many customers out there with the semiconductor and other areas who plan to make these relocations to make sure they understand the full benefit of our portfolio when they're ready to put in place manufacturing control systems to help them with our industrial solutions at the same time in the QC with our QC products and, of course, also in the R&D environment with the growth span of our research and development tools that we have for discussion. But so far, I would say the impact on our business from reshoring and homeshoring is not yet of any meaningful size, but we expect it to be an upside in the, let's say, quarters and years to come. Yeah. And we just feel like we're very well positioned for this trend as a global company. But also with our Spinnaker program, which really helps us to identify these types of opportunities.

Your next question comes from the line of Patrick Donnelly of Citi. Please go ahead.

Hey, guys. Thanks for taking the questions. Shawn, probably one for you on the tariff side. Appreciate all the color, the gross number, and some of the mitigation. Can you just break down kind of where that impact is coming from? Obviously, China was a pretty big concern coming in just in terms of some of the import-exports there. You talk about that impact? And then, again, the mitigation efforts that are ongoing, have you already started to move some things around? And then similarly on the pricing side, how should we be thinking about you guys are always quite nimble on pricing increases and surcharges? So we'd love to just talk through both the gross impact, where it's coming from, and then also the mitigation that are underway here.

Yeah. No. Hey, Patrick. Great questions. So I think the first comment is, of course, we already started to want to have more flexibility in our global supply chain going back coming out of COVID. So as part of that, we had expanded in Mexico, which was part of an acquisition that we did a while back. And then, you know, with this need to have more flexibility in our supply chain, we started to build out Mexico. More recently, with the global trade disputes kind of on the horizon, we've been accelerating a lot of our plans here. This is one example. Of course, we do a lot of things with our global supply chain. But we've been making a lot of progress in our optimization of our global supply chain processes here recently and made a lot of progress here already this year. As a result, our exposure to imports from directly from China, we estimate that number is more in the range of about $50 million right now. So, you know, previously, we would have said that that number was under a hundred. It was a little bit dynamic, and we wanted to see a little bit how things played out here with the timing of tariffs. But we're really pleased to make good progress in terms of that number. Of course, China, of course, Mexico is now higher than China, but, you know, expected to still be below a hundred million dollars. And then as we think about the rest of the world, you know, we expect imports to The U.S. to be in the range of about $250 million with a significant portion of that coming out of Switzerland.

Okay. And then just the pricing offsets, how you think about that?

Yeah. I'm sorry. That's the impact. Of course, and then the mitigation. So there's the supply chain. There is also some cost savings, and then there's pricing. So pricing, you know, we expect our pricing before we were communicating pricing to be kind of, like, in the range of about 2% for this year. Right now, we're thinking it's gonna be 3% or so. It will depend a little bit on how the tariffs play out because some of our pricing is gonna be price increases related to inflationary, you know, higher inflationary conditions that we expect from the trade war. But also a significant part of our mitigation actions also with surcharges, which gives us a little bit of flexibility as things can go up or down, you know, with the tariff rates. And so that could change a little bit going forward. But I think the flexibility will play out kinda well here as we kinda go forward. And, you know, and then as we kinda go into next year, you'll see the mix changing a little bit as we continue to work on supply chain optimization to put us in a position where we really have a lot of confidence in terms of our ability to mitigate the gross tariff headwind at the current rates.

Yeah. That's helpful. And then Patrick, maybe just on the industrial market overall, you know, that's become for the group, a little more concerning just given the macro backdrop, all the volatility out there. What are you hearing from customers on the core industrial piece? What's the right way to think about how you guys are forecasting that today versus maybe a few months ago when things were I guess, slightly different. Appreciate.

Yeah. Sure. I'll make a general comment on how I see the industrial end market and then let Shawn break it down of how we see the growth forecast for the second quarter and the full year. Look. I mean, I think we are exceptionally positioned with all product portfolio to serve the automation needs and digitalization needs in the industrial markets. And, yes, we have seen recently some delays with customers that had larger projects that moved. That's also why we see a bit of a slower movement in Q2 right now in industrial. But, overall, we are confident in our solutions that we see. The trend for automation, the need for automation given aging populations, reduction workforce worldwide, will stay in place. And if you take also into account the whole reshoring and homeshoring activities that are coming, these customers will not start with a lot of manual processes that they will try to start to automate as much as possible given also the higher labor cost they will face in the homeschooling countries. So I think that's why we're seeing currently some softness given the uncertainty think, for the long term, we are very well positioned with the portfolio. So can you break it down in terms of the industrial growth numbers for Q2 and the full year?

Yeah. Hey. So for on the industrial side for Q2, for core industrial, we've core industrial to be flat and we expect product inspection to be up mid-single digit. And for the full year, we expect core industrial to be flattish. And we expect product inspection to be mid-single digit.

Your next question comes from the line of Jack Meehan of Nephron Research. Please go ahead.

Hey, good morning, everyone. Wanted to continue on this topic of tariffs, but just in terms of customer behavior. I was curious if you saw any evidence of pull forward in the first quarter or any of like the April trends that you've seen so far?

Yep. Thanks, Jake. We have not seen a significant joining meaningful pull forward action in the quarter. I mean, I know there was something in the news of the car industry that but I would say our industry, we have not seen customers highlighting. They are placing orders earlier because they are concerned about the tariffs. So they are serving markets that are not really concerned about these very short-term moves, they also don't make a lot of short-term planning. That's what I see. But from what I'm hearing from the Salesforce, there has been not an acceleration of orders given the tariff impact.

Okay. Then within lab, I was curious just for some more color on the process analytics business. It had some encouraging commentary from some of your peers in the bioprocessing world. Curious how you feel about the setup there. Thank you.

Exactly. Yes. And we have seen also some really nice growth, and process analytics are also driven by some of the commands, of course, that you have heard from a lot of the biopharma customers that they really increase manufacturing to see a good increase of both single-use but also multi-use sensors in the space. But it has been a very healthy recovery also on the portfolio of single-use sensors, which have been, over the last years, subdued, there was also kind of no restocking issues in last year that has been fully resolved. And now we see some really healthy old income again.

Your next question comes from the line of Dan Arias of Stifel. Please go ahead.

Hey, good morning, guys. Thank you. Shawn, just a follow-up on manufacturing. The capabilities in Mexico, I think that's through Biokix, if I remember right. It used to be Pipette tips and life sciences reagents that you made down there. Have you expanded the production breadth beyond that at this point, or is it still focused on a subsegment of lab and so that's where the gross margin gains would be focused?

No. It's significantly expanded. We literally added on to the facility a few years ago, and we've been moving a wide range of products throughout the portfolio. Know, which will include lab industrial, and also on the food retailing side.

Okay. Helpful. And then just when it comes to the tariff obviously, you're implementing a plan today. If you were to get some de-escalation here, like, it's possible do you see the chance for some stickiness that could kind of leave the door open for a benefit relative to where things are today just in the sense that, you know, to your point, you have a low ASP portfolio. So if you were to raise some price in response to tariffs and then sort of align to a cost structure for a particular scenario, but then not have that scenario be the way that it plays out. Would you not necessarily have to pull it all the way back and so you could be left with some upside? Is the idea really to just sort of flex back down on pricing and surcharges as the situation changes?

And, hey, we'll see how things play out. Right? I mean, there's a lot of different scenarios that could happen. I mean, things have changed so much here in the last two to three months more than what we would have expected. Know, in terms of the surcharges. Of course, yes, they would you know, we'd have to pull them back if rates change, but we'll I think we'll just see how things play out here.

Yep. Yeah. Of course. But also on the manufacturing side, and as we have, you know, really increased our manufacturing footprint. For example, in Mexico, we also have put a lot of efforts into really making sure we establish a very strong local supply chain there, well, and that that is there to stay. I mean, we have a very competitive setup there to serve especially the North American market is that is some to some extent, redundant to the Chinese operation that we have as well. But given the again, given that the operate or the almost two years into the whole relocation or redundancy building, that will not will not pull that back. It will.

Got it. Okay. Thank you.

Your next question comes from the line of Brandon Couillard of Wells Fargo. Please go ahead.

Hey, good morning. Shawn, just wanted to clarify. When you're talking about seeing some orders being delayed, some pushouts for projects, is that isolated to core industrial? Was that a China-specific comment or more global?

My comment was specific to China that we sense that there's a little bit more you know, if you talk to the different regions, you know, if you talk directly to the sales organization, there's actually still a lot of optimism in the Western markets just given really good customer activity. But we're a little more cautious from the top down here just recognizing the situation. When we talk to maybe the Chinese organization, they're optimistic for the media, like going out a little bit, but they're a little bit more cautious in terms of just timing in the short term if you kinda look at their Q2 outlook. So that's an area where we're feeling a little bit more hesitation from customers to delay things a little bit here, kind of a wait-and-see mode. Kinda makes sense. Right? When you look at the significant level of tariffs. That are going on, I'm sure some companies are gonna try to take a wait-and-see approach just to see how it plays out a little bit. Fortunately, for us, Brandon, though, maybe it's a good point to comment on is if you look at our customers in China, you know, we're not typically selling to the exporters, you know, a very significant part of our business there is still our core markets, which are serving the local market. You know, we've talked a lot in the past about you know, I think something like 15% or less of our business is actually sold to multinationals. And then, you know, within that, Chinese portion of most of its private companies, and like I said, most of a very small portion of that relates to actually exporters. And a lot of what we're doing is actually supporting them with their own strategic initiatives to build up their own life science industry, etcetera.

Okay. That's helpful. And then Shawn, it doesn't look like your free cash flow guide actually changed at all. How do you just, I guess, approach managing working capital in this environment? And are you taking down or pushing out your own CapEx? Does it you know, the free cash flow number is actually the same.

Yeah. Yeah. Hey. I think we still feel good about it. We'll, you know, we'll revisit it as we go along. We, you know, we felt like we did pretty good here in the first quarter, especially if you exclude the timing of the bonus payments year on year related to prior year performance. You know, I think we were up you know, was it, like, 17% on a per share basis or something like that? And so I feel like, I feel like we had a good first quarter of course, we're looking at things to kinda optimize things in terms of how we think about other types of, you know, line items on the cash flow statement too that, you know, will allow us to continue to reinvest in our business as we expect, but also just maybe optimize things in terms of how we you know, how we can benefit from this year in this environment. But, you know, we'll see how things play out here a little bit.

Your next question comes from the line of Vijay Kumar of Evercore ISI. Please go ahead.

Hey, guys. Thanks for taking my question. Shawn, maybe my first one on the guidance cadence here. Q1 ex the shipping delays, you guys up 3% low singles. Q2, zero to one, what drives that step down in revenues? Are you assuming some demand is destruction because of tariffs here in Q2? And I think, like, the back half sort of assumes you step back to three plus to hit the annual. So maybe just talk about this, cadence for Q2 and back half.

Yeah. I mean, if I think if you kinda, like, cut through our guidance and you look at price versus volume, you're right. Q2 will be kind of the low point of the year. I think it's very much related to these comments on uncertainty in the short term. With, you know, maybe more optimism in the medium term. And part of that part of that caution in the short term is gonna be is gonna be China. But I think, you know, maybe just to kinda, like, look at the regions here, I mean, we are expecting know, kinda, flattish results here. In lab and industrial. We already talked about mid-single digit and product inspection. We expect retail to be down a little bit in Q2. But then from a regional perspective, we expect know, The Americas to be flattish to up low single digits. So probably another area where there's a little bit of caution. And then with Europe up low single digit, and we already talked about China being like, down low to mid-single digits. So maybe the two areas that jump out a little bit were China comments and then maybe just a little bit more cautious on The Americas in the short term.

Understood. And my follow-up here on tariffs, I think you said $50 million was China. The overall $115 million when you say annualized, what is the impact for fiscal 'twenty-five? Is that something lesser because you're using annualized.commons in a thing?

Yeah. So I think maybe yeah. So maybe one way to think about it not to put an exact number on it, is about 7% It'll probably be about a 7% gross headwind to EPS. Know, in terms of the tariff impact this year. And, you know, we expect to offset know, probably 75% or more of that. You know, this year, which would result in a net headwind to EPS of about 2%.

Sorry. I'm just looking at a follow-up on like, the I think you used a carriage about current levels in your remarks. So is are we assuming the current, I guess, rates of sustain, or are you is the guide assuming you know, post the ninety-day pause for rates to tariff rates to creep back up, like, what is the guide assuming on tariffs?

Yeah. No. Good question. We assume that it's at current rates. We assume it's at current rates. And recognizing it can go up or down. Know, so and, you know, we'll see.

Maybe taking the China questions in a different angle. Do you think that if this tariff situation lasts a little bit longer than expected, meaning beyond Q2, there could be some shifts in the competitive landscape in China, meaning the local players would maybe prefer local substitution if possible from a technology performance standpoint, because of pricing, and that could shift things if this longer than expected? Do you feel pretty comfortable with your competitive positioning to kinda penetrate through these near-term issues?

Yeah. Thanks, Matt. Look. I mean, first, I think you want to appreciate that most of the product that we sell in China, we actually manufacture in China. So we import very little from the U.S. to China. So while there's a bit of tariff headwind there as well, it's much, much more than the other direction because most products that we sell in China, manufacture in China, a very, very competitive in a very competitive situation, but also ourselves being in a very, very good position. There because we source locally. We have manufacturing locally. We have a strong local marketing team. And from many perspectives, our customers here is almost like a Chinese company because we are fully merged there with the customers. We are very quick adopting how to do local application demand changes, etcetera. We think we can continue to very effectively in the local market with our setup there. And the few products that we still manufacture in The U.S. or in Germany or in Switzerland and ship them to China. We are looking also there into options to localize some of them, but it, of course, depends on our priorities and also on IP questions, etcetera. But the exposure of this of that tariff in China for U.S. product is for us rather small. And if we think we are set up for long-term good competitive position in the market.

Got it. Thank you for that. And maybe just two quick ones. Patrick, one for you just on services growth. You said 6% in the quarter. A little bit below kind of the run rate you were doing last year, if I recall correctly. I'm sure some of this is comps just maybe talk about the underlying strength that you continue to have confidence in that services growth. And then Shawn, just could you just I'm sorry if I missed this, but just any FX assumptions in the EPS guide over the course of the year that might have offset some of the tariff impact?

Thanks, Ian. I'll start with services questions. Yes. Q1 was a bit of a tougher compare compared to last year, but we are still pretty pleased with the 6% growth that we have seen in Q1. For the full year, we forecast mid to high single-digit growth in 2025. We have invested a lot also last year into growth program services to make sure that we really can tap deeper into the install base that is currently not serviced. By our team. So we have implemented more marketing and telesales resources to reach out to customers, have real sales programs in place, also added a significant number of new service people in the field. So I think that whole growth program is still a long runway. And I'm actually quite pleased with the outlook and what I'm hearing from the team. Also want to recognize the team here for having really outstanding feedback from our customers in terms of Net Promoter Scores. They are higher than ever. It also tells me that our customers are really pleased with the service certificate.

But, hey, maybe the second part of your question, Matt. So we reduced our full-year EPS guidance by 2% at the high end of our range and 2.5% at the midpoint. At the midpoint, about two-thirds of that relates to the gross tariffs offset by our mitigation actions. The other third reflects the lower sales volume for the year. Offset by better operating performance. And more favorable foreign currency. So currency we expect from an EPS perspective to be at current rates flattish or neutral for the year. And then, you know, last quarter, we were expecting it to round to, like, a 2% kind of a headwind.

Your next question comes from the line of Doug Schenkel of Wolfe Research. Please go ahead.

Good morning. This is Avery on for Doug. Thank you for the Just looking at your margin for the quarter, obviously, have the shipping impact, but gross margin was up 30 basis points. I was just wondering if there's any favorable mix there. And then looking at the OpEx line, it seems like that number was a bit elevated in dollar terms, specifically SG&A. So just wondering if you could give any color there. Was that preparation being done in advance of the tariffs? And then going forward through the balance of this year, would it make sense to expect that level of OpEx as a percentage of sales to be somewhat elevated relative to last year?

Yeah. Hey. So, you know, in terms of the gross margin for the quarter, we were actually very pleased with our gross margin a little bit better than what we had expected. It was up 30 bps but if you exclude the impact of the shipping delays from a year ago, it was up 90 bps. You know, we had good performance in pricing. It came in about two in the 2% kind of a range, but we also saw some good progress continued on our sterndrive program and productivity initiatives in the company. In terms of mix, there might have been I think there was a little bit of favorable mix there as well too. In the quarter as well. But, otherwise, we feel good about the performance. And then, you know, if you kinda, like, look through the year, there's a lot of moving parts this year. But if you kind of, like, kind of exclude the shipping delay, topic, you exclude the tariff net of our mitigation actions, our gross margin is probably up in the 30 basis points kind of a range, which given the top line not having the volume that maybe we expected at the beginning of the year, we feel actually pretty good about that. You know, in terms of SG&A, of course, there's always gonna be you know, we are investing in the business. You know, we, you know, this was an important topic for us to as we entered the year in terms of continuing to drive growth in the business. We have a lot of great programs, a lot of great ideas, and, you know, we're gonna continue to do that. But, you know, when you look at one quarter versus another, there's you know, there can always be a little bit of timing, you know, and so I wouldn't you know, try to overread from one quarter to another quarter. You know? And, of course, we're gonna you know, we're gonna look at non-sales activities for the rest of the year and to be a little bit more cautious you know, until we get a little bit more clarity on the top line. But I think if you just kinda cut through everything and you at our operating margin for the full year and you kind of exclude the shipping delay topic from last year, which is like, a headwind of about 60 basis points. And if you on a reported basis, maybe we're gonna be down by about, like, a 30 bps. But if you exclude the shipping delay topic, which is about a 60 basis point headwind, and if you exclude the tariff costs and the net and the mitigation activities, you know, our operating margin is probably up slightly for the full year.

Thanks. Operator, your next question comes from the line of Rachel Vatnsdal of JPMorgan. Please go ahead.

Perfect. Good morning, and thanks so much for taking the question. First off, I just wanted to dig into Vijay's question earlier on the second quarter guide and the implied back half range. You highlighted some of the customer caution primarily impacting the second quarter. Can you just walk us through do you think most of this customer caution in light of the macro environment is mainly going to impact the second quarter? And which segments are you expecting to see the most improvement as we get into the back half of the year on that customer caution as well?

Yep. So if you kinda look at the second half, just to keep in mind, Rachel, the second half will benefit from pricing, you know, relative to, like, Q1. So I think if we kinda just, like, look at volume in the second half versus volume in the first half, and when I say the first half, I mean, it excluding the shipping delay in Q1. Probably pretty similar. And so, you know, our view is that at the beginning of the year, our guidance assumed that things were gonna improve in the second half of the year. Right now, we're kinda taking that off the table for the moment, and we're just saying that we think things will probably be more consistent for the second half of the year on a volume basis. But we do have some benefit a little bit on pricing in the second half relative to the first half. In terms of the pieces, of course, I understand where your question's coming from, but it's pretty dynamic. You know? I mean, probably the one number I'll provide is that our pricing assumption for the year was 2%. We expect it to be more at 3% or so now for the full year, so that kinda gives you maybe some context for what we're doing. Of course, pricing is something we can do quicker than on the supply chain side. That pricing will have an element, like I mentioned before, price increases and surcharges. So it might go up or down on the surcharge side. So that's a little bit you know, something that could be a little bit fluid as we kinda go through the year. As we kinda get to the end of the year, we you know, or maybe even better said, as we go into 2026, you know, we're gonna see a lot of the supply chain optimization kicking in a lot kinda going into next year and, you know, precise timing, you know, things will happen throughout the year, but the reality is is that we're accelerating a lot of things. And it's probably best just to think of them as being in place by the end of this year. We kinda go into next year. And, yeah, if we go a little bit faster, maybe there's a little bit of upside, but it's gonna take some time to do some of these things. And the other thing is is like, hey, we've already done a lot on the supply chain optimization side in terms of you know, already mitigating the gross tariff headwind, which we actually feel quite good about with our supply chain processes.

Your next question comes from the line of Royston of Bank of America. Please go ahead.

Thanks for taking the question, guys. For my first one, you touched on a lot of these things earlier. You talked about industrial a lot. You talked about China. I'm just kinda hoping to get it in one place and maybe bring all those topics together. In terms of the, you know, fiscal year twenty-five guide, the reduction in one of one and a half percent local currency from three to know, one to 2% now. Any way you could just sort of bridge that for us? How much of that 50 bps reduction is China? How much is lab, industrial, whatever way you think makes the most sense just so we can see sort of what what's changed, obviously, and where you're signing those cuts.

Yeah. So, you know, I think you could probably do the math with me a little bit here. But, you know, before we were saying you know, China was gonna be up low single digit for the full year, and now we're saying it's down slightly. So that might be about a point in itself. You know? And then in terms of other changes, you know, we're taking down You know, both The Americas and Europe were at mid-single digit before, and, you know, on a reported basis. And that was, I'm sorry, excluding, the shipping delay. Topic. And so now, Americas is down more, like, low single digit excluding the shipping delay. So it would be you know, yeah, actually both on a reported and excluding shipping delay. And then Europe is maybe just slightly lower than expected. And then in terms of, like, the divisional you can kinda see probably the one thing that kinda jumps out is, you know, before on an adjusted for the shipping delay basis, You know, we were saying lab might be mid to high. Now we're saying like, more, like, mid. And then we were saying, you know, industrial would be up low single digit on an excluding the shipping delay, and now we would say it would be more flattish.

Okay. That's a great summary of all that. And then I guess, I'll keep it the one follow-up. You haven't directly addressed NIH, U.S. government, I know it's a relatively small part of your exposure, but still there's some there, especially if think sort of the lab, pipettes, some of those more some balances. Just what's been going on in that end market? If you've seen any meaningful change from customer behavior Someone asked about stocking earlier. It sounds like that hasn't happened, but just sort of your thoughts on U.S. A and G, U.S. NIH? Thanks.

Yeah. So, I mean, of course, our direct exposure to NIH is closer to zero than it is to one. But if you look at our broader academia exposure in The U.S., And you look just look at our U.S. academia exposure. It's about 2% of our global sales. And then if we add in government, it probably gets about 3%. So it's and I'm talking specifically the U.S. A and G as a percentage of our total sales. So smaller part of our business, but certainly a part of the business that is we are seeing under pressure in, you know, doesn't have a big impact on our numbers, but certainly, you know, it's adding to a little bit of, you know, the headwind that we see in The Americas here, especially in the short term.

Your next question comes from the line of Tycho Peterson with Jefferies. Please go ahead.

Maybe just to kinda round it out on lab. I'm just I wanna probe it to pharma a little bit. You know, you touched on bioprocess earlier to Jack's question, but you know, pharma specifically, can you maybe talk about what you're hearing from your customers there? Any concerns about them leaning on you guys on prices? They have to respond to tariffs. How do you think about the replacement cycle? Because you've talked about that as an opportunity as well.

Yeah. Good. Thanks. I'll take that one. We are actually not hearing from our pharma customers yet any big impact in terms of their pricing concerns. We have very healthy engagement with pharma, small molecule, and large molecule customers right now. I think they're excited about the lab portfolio we have including the automation features. So not that not I would say no not a negative impact yet. I mean, we'll see what if there's anything else coming up, but what I'm hearing from the Salesforce is very strong positive engagement with pharma customers.

Okay. Maybe another angle on China, manufacturing you know, some of your large multinational competitors, including your biggest one in balances and skills, you know, doesn't do a lot in China. And so is there an opportunity to gain share here for you guys? Given your manufacturing, you know, footprint within the country?

Yep. Yeah. Maybe. Look at our team is very close to customers there. But they also want to remind you about of a total exposure to customers there in China is about 60% is actually local companies and only 15% on multinationals. And to have 25% of government and state-owned companies, So, yeah, we are talking to customers there. If there's more happening with companies in that space, we will definitely use some of worldwide food and the references we have from other countries. But yeah.

But, Tycho, if I understand your question, I think you mean, our competitiveness in China? You know, versus other competitors that don't I think if you have the multinational competitors that, you don't manufacture in China where you know? So you have a competitive advantage in China.

Yeah. Exactly. Yeah. Exactly. So I agree. I think we do have a competitive advantage in China versus a lot of our competition. And, you know, as you know, we've been there for a long time since the eighties. We not only manufacture mostly in China for China, but we actually develop a lot of products in China. So we really have a good sense in the strength of what the market expectations are at the right price points. And because of that, we've been very much perceived as a Chinese company over the years. And if we're not making it in China, we tend to import from Europe, like, specifically Switzerland. So, yeah, we feel good about our posture there in China. And, frankly, we feel like we're competing well globally in general against competition. Okay. Are you seeing any stimulus there?

Not really. Not a big change. I mean, there's talk about stimulus. And in the last stimulus program, our sales team was quite engaged with customers, helping again, bundling products together. To comply with benefit guidelines. But not right now any new stimulus that we would be aware of.

Your next question comes from the line of Catherine Schulte Baird. Please go ahead.

Hey, guys. Thanks for the questions. Maybe first just on tariffs. For the $100 million or maybe a little more imports into The U.S. that aren't coming from China and Mexico, how much of that is coming from Switzerland? I'm just trying to think about what the anchor incremental growth impact could be if the country-specific tariffs go into effect in July as proposed? Just given your Swiss exposure and, you know, how much of that you think could be offset if necessary?

Yeah. Hey, Catherine. So if you look at our exposure, you know, we've been very specific about our Chinese exposure, especially given the nature of the rates. So we expect it now to be more in the $50 million range. We've also given some color on Mexico given that such a significant moving piece and it relates to the China situation. You know, in terms of the rest of the world, we prefer not to go into every single country. But we would say that, you know, we are importing about $250 million into The U.S. from Europe and the rest of the world. And a significant portion of that is coming out of Switzerland.

Got it. And then maybe just on capital deployment. Any appetite to do more on the buyback side just given where the stock is today?

No. Hey. We you know, we're very consistent here. Right? We know, we don't try to time the market and, you know, we try to stick to exactly what we say at the beginning of the year. So, no, our assumptions are the same. For the year.

Your next question comes from the line of Josh Waldman of Cleveland Research. Please go ahead.

Good morning, guys. Thanks for squeezing me in. First, Patrick, a follow-up on core industrial. I think you mentioned softness in The U.S. in the prepared remarks. Is this primarily where you're lowering your outlook in core or are there other areas that are tracking below?

No. I'll take that, Josh. Look. It's more in China that we did lower the Outlook and Quantas industrial. In The U.S., what I referred to in Q2 was some delays of larger products. But these are really larger projects. Projects, industrial automation projects, and they not always really close within the time we noticed that the field initially thinks that we'll close. So we saw we forecast so we recently saw some forecast we made in Q2, but overall, the biggest takedown in industrial in the growth rate compared to what we said at in the last earnings call is that way in China.

Got it. Okay. Hector, can you remind us what portion of the business is sales to bioproduction OEMs? Maybe how business is tracking there, then if you're seeing any signs of onshoring in that business.

And you're talking about insurance for industrial. So we don't break that out, Josh, but we, you know, what we've said in the past is that about 60% of core industrial is a combination of pharma, biopharma, food manufacturing, and chemical. And for us, chemical means more specialty chem.

There are no further questions at this time. And with that, I will now turn the call back over to Adam Uhlman for closing remarks. Please go ahead.

Okay. Great. Thanks. Hey, everybody. If you have any questions, feel free to reach out to me, and I hope everybody has a great weekend. And take care. Bye.

Ladies and gentlemen, this concludes your conference call for today. Thank you for participating. You may now disconnect.